Peptide Knowledge Base · Metabolic

VK2735 (Viking): what it is, what the evidence says, and its real status

A dual agonist whose category-disrupting wrinkle is an oral form.

Can you actually get it?

Plain-English verdict: Education only.

Regulatory status: Investigational (Phase 2/3).

How does VK2735 (Viking) work?

A dual GLP-1/GIP receptor agonist; the oral formulation is the strategically notable feature versus injectable-only incumbents.

What it does — and what it does not do

What it does: Studied for weight reduction; an oral version is in development.

What it does not do: It is not approved, not available, and the oral-vs-injectable comparison is not yet settled in trials.

How honest is the evidence?

Evidence grade B — Good human evidence.

Phase-2 data; Phase-3 ongoing, re-verify

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Oral bioavailability, durability, and long-term safety are still being established.

WADA status: Not prohibited.

How it is taken

What the literature reports: injectable weekly or oral daily (under study). Educational only, no dose figures.

Who should not take it

Investigational, safety not fully characterized; clinician-gated.

Sources

VK2735 Phase-2 program · VANQUISH (ongoing, re-verify against primary sources)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.